Cosmo Pharmaceuticals - 股票

Cosmo Pharmaceuticals 负债 2024

Cosmo Pharmaceuticals 负债

0 EUR

股票代码

COPN.SW

ISIN

NL0011832936

WKN

A2AJ68

在2024年,Cosmo Pharmaceuticals的债务为0 EUR,与前一年-198.05 EUR的总债务相比变动了-100%

Cosmo Pharmaceuticals Aktienanalyse

Cosmo Pharmaceuticals在做什么?

Cosmo Pharmaceuticals NV is an international pharmaceutical company based in Dublin, Ireland. The company focuses on developing innovative drugs for various diseases, including gastroenterology, oncology, and infectious diseases. The history of Cosmo Pharmaceuticals dates back to 1997 when it was founded by Dr. Mauro Ajani in Italy. Since then, the company has undergone impressive development and is now listed on the SIX Swiss Exchange. In 2020, the company moved from Italy to Ireland to strengthen its international presence. Cosmo Pharmaceuticals' business model is based on creating patented innovations and technologies in drug development. The company works closely with other companies and research institutions to introduce a wide range of products that benefit both patients and healthcare providers. The main source of income for Cosmo Pharmaceuticals is the licenses they grant for their products, as well as the manufacturing and sale of their own products. Cosmo Pharmaceuticals operates three main business areas: Human, Veterinary, and Proprietary. The Human division specializes in the development of drugs for humans. The company's products are available worldwide, including in the United States, Europe, Japan, and China. In the field of gastroenterology, Cosmo Pharmaceuticals is one of the leading companies on the market and has developed several products to treat gastrointestinal problems and other gastrointestinal diseases. The Veterinary division of Cosmo Pharmaceuticals specializes in the development of animal medicines. The company works with veterinarians and pet owners to bring products to market that help animals stay healthy or recover. Cosmo Pharmaceuticals offers several products tailored to the specific needs of animals, including Ballistol Animal, used for skin and fur care, and Otilonium Bromide, used for digestive disorders in horses. The Proprietary division is the third major business area of Cosmo Pharmaceuticals. This is a segment that manufactures its own products and sells them directly to patients or institutions. The company's products include Eleview, used in endoscopy to improve visibility of the gastrointestinal mucosa. Cosmo Pharmaceuticals is an innovative company focused on the development of drugs that can help improve patients' lives. The company collaborates closely with other companies and research institutions to leverage the latest technologies and developments in the industry. With its broad portfolio of products in the field of gastroenterology, oncology, and infectious diseases, the company has a strong presence in the industry and actively advocates for more people to have access to the best medical treatments. Cosmo Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

负债的详细信息

Cosmo Pharmaceuticals的债务结构理解

Cosmo Pharmaceuticals的总债务是指该公司欠外部各方的累积金融义务。这可能包括短期和长期贷款、债券、贷款和其他金融工具。评估公司的债务对于评估其财务状况,风险概况以及运营和扩展业务的能力至关重要。

年对年对比

通过对Cosmo Pharmaceuticals多年债务结构的分析,可以洞察公司的财务策略和稳定性。债务的减少可能暗示了财务实力和运营效率,而债务的增加可能表明投资增长或潜在的财务挑战。

对投资的影响

投资者会密切关注Cosmo Pharmaceuticals的债务,因为这会影响公司的风险和收益概况。过度的债务可能导致财务压力,而适度并且管理良好的债务可能是增长和扩张的催化剂。这使得债务成为投资评估的重要一环。

债务波动的解读

Cosmo Pharmaceuticals债务水平的变化可能归因为各种运营和策略因素。债务的增加可能旨在资助扩张项目或提高运营能力,而债务的减少可能意味着利润的实现或是一种减小财务风险和杠杆效应的方法。

关于Cosmo Pharmaceuticals股票的常见问题

Cosmo Pharmaceuticals今年的债务有多高?

Cosmo Pharmaceuticals今年的债务水平为0 EUR。

Cosmo Pharmaceuticals的债务与去年相比有多高?

Cosmo Pharmaceuticals的债务与去年相比增长了-100% 下降了

Cosmo Pharmaceuticals的投资者高额债务会有什么后果?

对于Cosmo Pharmaceuticals的投资者来说,高额债务可能构成风险,因为它会使公司的财务状况变得较弱,可能会影响其履行义务的能力。

Cosmo Pharmaceuticals的投资者低债务会有什么后果?

低债务意味着Cosmo Pharmaceuticals拥有强大的财务地位,并且能够履行其义务,而不会导致其财务负担过重。

Cosmo Pharmaceuticals的债务增加对公司会有什么影响?

Cosmo Pharmaceuticals的债务增加可能会影响公司的财务状况,从而导致其财务负担增加。

Cosmo Pharmaceuticals的债务减少会对公司产生什么影响?

将Cosmo Pharmaceuticals的债务降低可以增强公司的财务状况并提高其履行财务义务的能力。

Cosmo Pharmaceuticals的债务受哪些因素影响?

影响Cosmo Pharmaceuticals负债的一些因素可能包括投资、收购、运营成本和营业收入的发展。

为什么Cosmo Pharmaceuticals的债务对投资者如此重要?

Cosmo Pharmaceuticals的债务对投资者来说很重要,因为它是公司财务稳定性的指标,并且能向投资者提供有关公司如何履行其财务义务的信息。

Cosmo Pharmaceuticals可以采取哪些战略措施来改变债务状况?

为了改变债务状况,Cosmo Pharmaceuticals可以采取包括削减成本、增加收入、出售资产、接受投资或合作伙伴关系等措施。公司必须对其财务状况进行彻底审查,以确定最佳的战略措施来改变其债务状况。

Cosmo Pharmaceuticals支付多少股息?

在过去的12个月中,Cosmo Pharmaceuticals支付了1.05 EUR 的股息。这相当于大约1.4 %的股息收益率。在未来的12个月内,Cosmo Pharmaceuticals预计将支付1.05 EUR的股息。

Cosmo Pharmaceuticals的股息收益率有多高?

Cosmo Pharmaceuticals当前的股息收益率为1.4 %。

Cosmo Pharmaceuticals什么时候支付股息?

Cosmo Pharmaceuticals按季度支付股息。这些股息将在, , , 月份分发。

Cosmo Pharmaceuticals的股息有多安全?

Cosmo Pharmaceuticals 在过去8年里每年都支付了股息。

Cosmo Pharmaceuticals的股息有多高?

预计未来12个月的股息将达到1.05 EUR。这相当于1.41 %的股息收益率。

Cosmo Pharmaceuticals位于哪个行业?

Cosmo Pharmaceuticals 被分配到“健康”板块。

Wann musste ich die Aktien von Cosmo Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

要获得Cosmo Pharmaceuticals在支付的2.17 EUR的最后一笔股息,你必须在的除息日之前持有该股票于你的账户中。

Cosmo Pharmaceuticals最后一次支付股息是什么时候?

上一次股息发放日期为。

Cosmo Pharmaceuticals在2023年的股息是多少?

在2023年,Cosmo Pharmaceuticals 分配了0.95 EUR作为股息。

Cosmo Pharmaceuticals 的股息是以哪种货币支付的?

Cosmo Pharmaceuticals的股息将以EUR的形式分配。

股票储蓄计划为投资者提供了一种吸引人的方法,可以长期累积财富。主要优势之一是所谓的成本平均效应:通过定期投入固定金额于股票或股票基金,当价格低时自动买入更多份额,价格高时买入较少,这可能随着时间带来更优惠的平均每份成本。此外,股票储蓄计划还允许小额投资者接触到高价股票,因为他们可以用很小的金额参与其中。定期投资也促进了一种纪律投资策略,并有助于避免情绪化的决策,如冲动买卖。除此之外,投资者还能从股票的潜在增值以及可以再投资的股息分红中获益,这增强了复利效应,从而增加了投资资本的增长。

Andere Kennzahlen von Cosmo Pharmaceuticals

我们对Cosmo Pharmaceuticals 营业额股票的股票分析包括重要的财务指标,如收入、利润、市盈率、市销率、息税折旧摊销前利润,以及有关股息的信息。此外,我们还研究了诸如股票、市值、债务、股东权益和Cosmo Pharmaceuticals 营业额的负债等方面。如果您在寻找关于这些主题的更详细信息,我们在子页面上提供了详细的分析: